Bevacizumab as treatment for chemotherapy-resistant pancreatic cancer

Anticancer Research

Volumn 25, Issue 5, 2005, Pages 3637-3639

  Bruckner, Howard W ^a   Hrehorovich, Victor R ^a   Sawhney, Harinder S ^a  

^a LUTHERAN MEDICAL CENTER   (United States)

Author keywords

Bevacizumab; Cisplatin; Fluorouracil; Gemcitabine; Irinotecan; Pancreatic neoplasms

Indexed keywords

BEVACIZUMAB; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CISPLATIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; TAXANE DERIVATIVE;

AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER STAGING; CASE REPORT; COMBINATION CHEMOTHERAPY; DOSE TIME EFFECT RELATION; HUMAN; LOW DRUG DOSE; MALE; PANCREAS CANCER; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT FAILURE;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CISPLATIN; DEOXYCYTIDINE; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; PANCREATIC NEOPLASMS;

EID: 23344447904     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Penland SK and Goldberg RM: Combining anti-VEGF approaches with oxaliplatin in advanced colorectal cancer. Clin Colorectal Cancer 4 supp 2: S74-80, 2004.
2. Kindler L, Friberg G, Stadler W, Singh D, Locker G, Nattam S et al: Bevacizumab plus gemcitabine is an active combination in patients with advanced pancreatic cancer: interim results of an ongoing phase II trial from University of Chicago Phase II Consortium. J Clin Oncol 2004, 2004 ASCO Annual Meeting Proceedings (Post meeting edition); 22: Abstract 4009.
3. Karademir S, Sokmen S, Terzi C, Sagol O, Ozer E, Astarcioglu H et al: Tumor angiogenesis as a prognostic predicator in pancreatic cancer J Hepatobiliary Pancreat Surg 7: 489-495, 2000.
4. Stipa F, Lucandri G, Limiti MR, Bartolucci P, Cavallini M, Di Carlo V et al: Angiogenesis as a prognostic indicator in pancreatic ductal adenocarcinoma. Anticancer Res 22: 445-449, 2002.
5. Hotz HG, Hines OJ, Masood R, Hotz B, Foitzik T, Buhr HJ et al: VEGF antisense therapy inhibits tumor growth and improves survival in experimental pancreatic cancer. Surgery 137: 192-199, 2005.
6. Kurbacher C, Bruckner H, Cree I, Andreotti P and Janat M: A prospective clinical trial on individualized chemotherapy for recurrent ovarian cancer selected by ex vivo ATP tumor chemosensitivity assay. Proc Am Soc Clin Oncol abstract 1384, 1999.
7. Kozuch P, Grossband ML, Barzdins A, Araneo M, Robin A, Frager D, Homel P, Marino J, DeGregorio P and Bruckner HW: Irinotecan combined with gemcitabine, 5-florouracil, leucovorin and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer. Oncologist 6: 488-495, 2001.
8. Gerber HP and Ferrera N: Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 65: 671-680, 2005.
9. Wildiers H, Guetens G, De Boeck G, Verbeken E, Landuyt B, Landuyt W et al: Effect of antivascular endothelial growth factor treatment on intratumoral uptake of CPT-11. Br J Cancer 88: 1979-1986, 2003.
10. Bocci G, Danesi R, Marangoni G, Fiaravanti A, Boggi U, Esposito I et al: Antiangiogenesic versus cytotoxic therapeutic approaches to human pancreas cancer: an experimental study with a vascular endothelial growth factor receptor -2 tyrosine kinase inhibitor and gemicitabine. Eur J Pharmacol 498: 9-18, 2004.
11. Allegrini G, Goulette FA, Darnowski JW and Calabresi P: Thrombospondin-I plus irinotecan, a novel antiangiogenic -chemotherapeutic combination that inhibits the growth of advanced human colon tumor xenografts in mice. Cancer Chemother Pharmacol 53: 261-266, 2004.
12. Zhong X, Li X, Wang G, Zhu Y, Hu G, Zhao J et al: Mechanism underlying the synergistic effect of SU5416 and cisplatin on cytotoxicity in human ovarian tumor cells. Int J Oncol 25: 445-451, 2004.
13. Ogawa H, Sato Y, Kondo M, Takahashi N, Oshima T, Sasaki F et al: Combined treatment with TNP-470 and 5-fluorouracil effectively inhibits growth of murine colon cancer cells in vitro and liver metastasis in vivo. Oncol Rep 7: 467-72, 2000.
14. Drevs J, Fakler J, Eisele S, Medinger M, Bing G, Esser N et al: Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy. Anticancer Res 24: 1759-1763, 2004.
15. Hahnfeldt P, Folkman J and Hlatky L: Minimizing long-term tumor burden: the logic for metronomic chemotherapy dosing and its antiangiogenic basis. J Theor Biol 220: 545-554, 2003.
16. Gately S and Kerbel R: Antiangiogenesis scheduling of lower dose cancer chemotherapy. Cancer J 7: 427-36, 2001.
17. Bruckner H, Bathini D, Zak D, Reilly J, Degregorio P, Marino J et al: Drug integration based laboratory designed combination chemotherapy for pancreatic cancer. Proc Am Soc Clin Oncol 22: 371(abstact 1490), 2003.
18. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342, 2004.
19. Hainsworth J, Sosman A, Spigel D, Schwert R, Carrell D, Hubbard F et al: Phase II trial of bevacizumab and erlotonib in patients with metastatic renal cell carcinoma (RCC). J Clin Oncol, ASCO Annual Meeting Proceedings 22: 4502, 2004.
20. Cobleigh MA, Langmuir VK, Sledge GW, Miller KD, Haney L, Novotny WF et al: A phase I/II dose -escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 30: 117-124, 2003.
21. Yang J, Haworth L, Steinberg S, Rosenberg S and Novotny W: A randomized double-blind placebo-controlled trial of bevacizumab (anti-VEGF antibody) demonstrating a prolongation in time to progression in patients with metastatic renal cancer. Proc Am Soc Clin Oncol abstact 15, 2002.
22. Dunn J, Stocken D, Almond J, Bakkevold K, Jeekel J, Douglass Jr H, Bassi C, Derevenis C, Fernandez-Cruz L, Lacaine F, Buchler M and Neoptolemos J: Meta-analysis of adjuvant chemoradiotherapy and chemotherapy for resectable pancreatic cancer including the final results of ESPAC I trial. Proc Am Soc Clin Oncol abstract 564, 2002.
23. Pirozzi VJ, Kozarek RA and Traverso LW: Interferon based adjuvant chemoradiation after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am J Surg 185: 476-480, 2003.
24. von Marshall Z, Scholz A, Cramer T, Schafer G, Schirner M, Oberg K, Wiedenmann B, Hocker M and Rosewicz S: Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. J Natl Cancer Inst 95: 437-438, 2003.